## Jinsil Seong

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8040242/publications.pdf

Version: 2024-02-01

186

all docs

101543 4,658 183 36 h-index citations papers

186

g-index 186 4374 times ranked docs citations citing authors

138484

58

#	Article	IF	CITATIONS
1	Dose-response relationship in local radiotherapy for hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics, 2002, 54, 150-155.	0.8	249
2	Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. International Journal of Radiation Oncology Biology Physics, 2003, 55, 329-336.	0.8	160
3	Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics, 1999, 43, 393-397.	0.8	153
4	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer, 2008, 113, 995-1003.	4.1	138
5	Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiotherapy and Oncology, 2019, 131, 135-144.	0.6	118
6	Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 121-129.	3.7	116
7	Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. International Journal of Radiation Oncology Biology Physics, 2000, 47, 1331-1335.	0.8	115
8	Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver International, 2005, 25, 1189-1196.	3.9	111
9	Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver International, 2005, 25, 261-265.	3.9	108
10	Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. Oncology, 2011, 81, 158-164.	1.9	104
11	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget, 2017, 8, 41242-41255.	1.8	89
12	Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. Journal of the National Cancer Institute, 2016, 108, djw133.	6.3	79
13	Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cellular Immunology, 2012, 278, 76-83.	3.0	75
14	Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiotherapy and Oncology, 2019, 131, 81-87.	0.6	70
15	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiotherapy and Oncology, 2018, 129, 130-135.	0.6	69
16	A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver International, 2009, 29, 147-152.	3.9	65
17	Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiation Oncology Journal, 2016, 34, 160-167.	1.5	60
18	Reirradiation to the pelvis for recurrent rectal cancer. Journal of Surgical Oncology, 2012, 105, 637-642.	1.7	59

#	Article	IF	CITATIONS
19	Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver International, 2017, 37, 90-100.	3.9	58
20	Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma. Yonsei Medical Journal, 2009, 50, 601.	2.2	57
21	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. Annals of Surgical Oncology, 2014, 21, 3646-3653.	1.5	53
22	Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer, 2016, 5, 162-174.	7.7	53
23	Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatology Research, 2003, 27, 30-35.	3.4	48
24	Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiotherapy and Oncology, 2017, 123, 438-445.	0.6	48
25	Radiotherapeutic Parameters Predictive of Liver Complications Induced by Liver Tumor Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 154-158.	0.8	47
26	<sup>18</sup> Fâ€fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer, 2011, 117, 4779-4787.	4.1	47
27	Strategic application of radiotherapy for hepatocellular carcinoma. Clinical and Molecular Hepatology, 2018, 24, 114-134.	8.9	47
28	Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer, 2017, 6, 264-274.	7.7	46
29	CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1148-1154.	0.8	45
30	The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy. Gut and Liver, 2018, 12, 342-352.	2.9	43
31	Gastroduodenal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1343-1351.	0.8	42
32	Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 2018, 25, 3308-3315.	1.5	42
33	Early alteration in TGF-Î <sup>2</sup> mRNA expression in irradiated rat liver. International Journal of Radiation Oncology Biology Physics, 2000, 46, 639-643.	0.8	41
34	Clinical Usefulness of 18F-Fluorodeoxyglucose-Positron Emission Tomography in Patients With Locally Advanced Pancreatic Cancer Planned to Undergo Concurrent Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 126-133.	0.8	41
35	Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Digestive and Liver Disease, 2019, 51, 445-451.	0.9	41
36	Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Medical Journal, 2016, 57, 1276.	2.2	39

#	Article	IF	Citations
37	Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget, 2016, 7, 40756-40766.	1.8	39
38	Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1595-1605.	2.5	38
39	Radiotherapeutic Options for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Liver Cancer, 2014, 3, 18-30.	7.7	38
40	Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients. Cancer Research and Treatment, 2016, 48, 583-595.	3.0	38
41	A Novel Combination Treatment of Armed Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Radiotherapy in Murine Hepatocarcinoma. Journal of Radiation Research, 2011, 52, 646-654.	1.6	34
42	Early Clinical Experience and Outcome of Helical Tomotherapy for Multiple Metastatic Lesions. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1517-1524.	0.8	33
43	Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.  Cancer Chemotherapy and Pharmacology, 2013, 71, 165-173.	2.3	33
44	Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. International Journal of Radiation Oncology Biology Physics, 2014, 89, 804-813.	0.8	33
45	A Prospective Phase 2 Multicenter Study for theÂEfficacy of Radiation Therapy Following Incomplete Transarterial Chemoembolization inÂUnresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1051-1060.	0.8	32
46	Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. International Journal of Cancer, 2015, 137, 721-730.	5.1	31
47	Early onâ€treatment predictions of clinical outcomes using alphaâ€fetoprotein and desâ€gammaâ€carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 313-322.	2.8	30
48	Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiotherapy and Oncology, 2019, 133, 1-8.	0.6	30
49	Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma1. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 883-889.	2.8	29
50	Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1037-1042.	0.8	29
51	Clinical usefulness of double biomarkers <scp>AFP</scp> and <scp>PIVKA</scp> â€ <scp>II</scp> for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver International, 2014, 34, 313-321.	3.9	29
52	The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size. Journal of Korean Medical Science, 2009, 24, 242.	2.5	27
53	Usefulness of Positron Emission Tomography With Fluorine-18-Fluorodeoxyglucose in Predicting Treatment Response in Unresectable Hepatocellular Carcinoma Patients Treated With External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1172-1178.	0.8	27
54	Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2019, 195, 1007-1017.	2.0	27

#	Article	IF	CITATIONS
55	Therapeutic benefit of radiotherapy in huge (≥10Âcm) unresectable hepatocellular carcinoma. Liver International, 2014, 34, 784-794.	3.9	26
56	Redox Signaling by Ionizing Radiation in Mouse Liver. Annals of the New York Academy of Sciences, 2004, 1030, 86-94.	3.8	25
57	Radiotherapeutic Strategies in the Management of Hepatocellular Carcinoma. Oncology, 2011, 81, 123-133.	1.9	24
58	Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 464-473.	0.8	24
59	Combination of Radiotherapy and Adenovirus-Mediated p53 Gene Therapy for MDM2-Overexpressing Hepatocellular Carcinoma. Journal of Radiation Research, 2012, 53, 202-210.	1.6	23
60	Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. Journal of Radiation Research, 2014, 55, 113-120.	1.6	23
61	Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma. Yonsei Medical Journal, 2018, 59, 470.	2.2	23
62	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology, 2020, 148, 73-81.	0.6	23
63	The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma. Gut and Liver, 2012, 6, 139-148.	2.9	23
64	Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). PLoS ONE, 2016, 11, e0152642.	2.5	22
65	Multidisciplinary Management of Nonresectable Hepatocellular Carcinoma. Oncology, 2011, 81, 134-140.	1.9	21
66	Selection of the Optimal Radiotherapy Technique for Locally Advanced Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 2011, 41, 882-889.	1.3	21
67	Inhibition of IL-17A Suppresses Enhanced-Tumor Growth in Low Dose Pre-Irradiated Tumor Beds. PLoS ONE, 2014, 9, e106423.	2.5	20
68	The significance of ICGâ€R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver International, 2012, 32, 1165-1171.	3.9	19
69	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer, 2015, 4, 96-105.	7.7	19
70	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 106-115.	0.8	19
71	Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis. International Journal of Radiation Oncology Biology Physics, 2003, 57, 282-288.	0.8	18
72	Is Local Radiotherapy Still Valuable for Patients With Multiple Intrahepatic Hepatocellular Carcinomas?. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1433-1440.	0.8	18

#	Article	IF	CITATIONS
73	Concurrent Chemoradiotherapy Shows Long-Term Survival after Conversion from Locally Advanced to Resectable Hepatocellular Carcinoma. Yonsei Medical Journal, 2014, 55, 1489.	2.2	18
74	Prognostic Values of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 in Hepatocellular Carcinoma after Radiotherapy. Digestive Diseases, 2014, 32, 725-732.	1.9	18
75	Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05). Cancer Research and Treatment, 2019, 51, 1589-1599.	3.0	18
76	Enhancement of Tumor Radioresponse by Wortmannin in C3H/HeJ Hepatocarcinoma. Journal of Radiation Research, 2007, 48, 187-195.	1.6	17
77	Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlentherapie Und Onkologie, 2017, 193, 620-629.	2.0	17
78	A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiotherapy and Oncology, 2018, 129, 340-346.	0.6	17
79	Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and metaâ€analyses. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 812-821.	1.8	17
80	Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2693-2700.	2.5	17
81	Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma. Cancer Research and Treatment, 2018, 50, 646-657.	3.0	17
82	Predictive Factors of Palliative Radiotherapy Response and Survival in Patients with Spinal Metastases from Hepatocellular Carcinoma. Gut and Liver, 2015, 9, 94-102.	2.9	17
83	Radiosensitizers in Hepatocellular Carcinoma. Seminars in Radiation Oncology, 2011, 21, 303-311.	2.2	16
84	Effective Biliary Drainage and Proper Treatment Improve Outcomes of Hepatocellular Carcinoma with Obstructive Jaundice. Gut and Liver, 2014, 8, 526-535.	2.9	16
85	Multimodality Treatment Involving Radiotherapy for Advanced Liver-Confined Hepatocellular Carcinoma. Oncology, 2014, 87, 90-98.	1.9	16
86	Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 405-416.	7.7	16
87	Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration. Yonsei Medical Journal, 2016, 57, 41.	2.2	16
88	Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer. Radiotherapy and Oncology, 2020, 151, 82-87.	0.6	16
89	Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 35-44.	3.7	16
90	Spontaneous Apoptosis as a Predictor of Radiotherapy in Patients with Stage IIB Squamous Cell Carcinoma of the Uterine Cervix. Acta Oncol $\tilde{A}^3$ gica, 1999, 38, 449-454.	1.8	15

#	Article	IF	Citations
91	Treatment of nonâ€resectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S424-7.	2.8	15
92	Identification of Proteins Indicating Radiation-induced Hepatic Toxicity in Cirrhotic Rats. Journal of Radiation Research, 2010, 51, 643-650.	1.6	15
93	High-dose Helical Tomotherapy With Concurrent Full-dose Chemotherapy for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1448-1454.	0.8	15
94	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: AAPropensity Score Matching Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 396-406.	0.8	15
95	Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). Oncotarget, 2017, 8, 94450-94461.	1.8	15
96	Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Research and Treatment, 2016, 48, 190-197.	3.0	15
97	Combined treatment of radiotherapy and hyperthermia for unresectable hepatocellular carcinoma. Yonsei Medical Journal, 1994, 35, 252.	2.2	14
98	Radiation-Induced Alteration of Pain-Related Signals in an Animal Model with Bone Invasion from Cancer. Annals of the New York Academy of Sciences, 2004, 1030, 179-186.	3.8	14
99	Neonatal capsaicin treatment in rats affects TRPV1-related noxious heat sensation and circadian body temperature rhythm. Journal of the Neurological Sciences, 2014, 341, 58-63.	0.6	14
100	Interobserver variability in gross tumor volume delineation for hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2016, 192, 714-721.	2.0	14
101	Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?. Yonsei Medical Journal, 2018, 59, 912.	2.2	14
102	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS ONE, 2019, 14, e0223678.	2.5	14
103	Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 468-479.	7.7	14
104	Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. Radiotherapy and Oncology, 2020, 152, 1-7.	0.6	14
105	Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 919-927.	3.3	14
106	Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer. Radiation Oncology, 2021, 16, 161.	2.7	14
107	Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). Cancer Research and Treatment, 2017, 49, 61-69.	3.0	14
108	A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 841-846.	2.3	13

#	Article	IF	CITATIONS
109	Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World Journal of Gastroenterology, 2017, 23, 2077.	3.3	13
110	Adaptive response to ionizing radiation induced by low dose of gamma ray in human hepatoma cell lines. Yonsei Medical Journal, 1994, 35, 77.	2.2	12
111	Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). International Journal of Radiation Biology, 2020, 96, 759-766.	1.8	12
112	Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. Cancer Research and Treatment, 2014, 46, 348-357.	3.0	12
113	Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies. Liver International, 2014, 34, 462-468.	3.9	11
114	<scp>FDG</scp> â€ <scp>PET</scp> predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. Liver International, 2014, 34, 1118-1125.	3.9	11
115	Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0157196.	2.5	11
116	Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2020, 196, 132-141.	2.0	11
117	Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2435-2445.	2.5	11
118	High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma. Oncotarget, 2016, 7, 53921-53929.	1.8	11
119	Effect of Interleukin-7 on Radiation-Induced Lymphopenia and Its Antitumor Effects in a Mouse Model. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1559-1569.	0.8	10
120	Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis. Gut and Liver, 2017, 11, 535-542.	2.9	9
121	A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers. Journal of Radiation Research, 2019, 60, 242-248.	1.6	9
122	Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?. Oncologist, 2020, 25, e1249-e1250.	3.7	9
123	Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic Cells. PLoS ONE, 2016, 11, e0146463.	2.5	9
124	Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08). Japanese Journal of Clinical Oncology, 2022, 52, 616-622.	1.3	9
125	Enhancement of Tumor Response by Farnesyltransferase Inhibitor in C3H/HeJ Hepatocarcinoma. Annals of the New York Academy of Sciences, 2004, 1030, 95-102.	3.8	8
126	Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. Journal of Radiation Research, 2013, 54, 1069-1077.	1.6	8

#	Article	IF	CITATIONS
127	Combination therapy with antiâ€Tâ€cell immunoglobulin and mucinâ€domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1357-1365.	2.8	8
128	Radiation-Induced CXCL12 Upregulation via Histone Modification at the Promoter in the Tumor Microenvironment of Hepatocellular Carcinoma. Molecules and Cells, 2019, 42, 530-545.	2.6	8
129	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers, 2022, 14, 2396.	3.7	8
130	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. Oncotarget, 2017, 8, 79914-79926.	1.8	7
131	Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer. Radiation Oncology Journal, 2014, 32, 7.	1.5	7
132	Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. Journal of Radiation Research, 2015, 56, 37-45.	1.6	6
133	What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma?. Journal of Clinical Oncology, 2018, 36, 2560-2561.	1.6	6
134	Optimal Timing of Radiotherapy after Incomplete Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 409.	2.2	6
135	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 403-412.	3.7	6
136	Helical tomotherapy for spine oligometastases from gastrointestinal malignancies. Radiation Oncology Journal, 2011, 29, 219.	1.5	6
137	Enhancement of Radioresponse of Murine Tumors by ERK Inhibitor. Annals of the New York Academy of Sciences, 2002, 973, 371-373.	3.8	5
138	Multimodality Treatment with Radiotherapy for Huge Hepatocellular Carcinoma. Oncology, 2014, 87, 82-89.	1.9	5
139	Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. Liver Cancer, 2016, 5, 139-151.	7.7	5
140	Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alphaâ€foetoprotein and <sup>18</sup> Fâ€fluoroâ€2â€deoxyglucose positron emission tomography. Liver International, 2017, 37, 592-599.	3.9	5
141	Dose perturbation by metallic biliary stent in external beam radiotherapy of pancreato-biliary cancers. Australasian Physical and Engineering Sciences in Medicine, 2019, 42, 745-756.	1.3	5
142	Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). European Journal of Cancer, 2021, 157, 31-39.	2.8	5
143	Altered Biological Potential and Radioresponse of Murine Tumors in Different Microenvironments. Cancer Research and Treatment, 2016, 48, 727-737.	3.0	5
144	Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis. Gut and Liver, 2014, 8, 557-562.	2.9	5

#	Article	IF	CITATIONS
145	Radiation-Induced CXCL12 Upregulation via Histone Modification at the Promoter in the Tumor Microenvironment of Hepatocellular Carcinoma. Molecules and Cells, 2019, 42, 502.	2.6	5
146	Radiological–pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1619-1627.	2.8	4
147	Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer. Strahlentherapie Und Onkologie, 2018, 194, 1017-1029.	2.0	4
148	Role of Interleukin-7 in the Development of and Recovery from Radiation-Induced Lymphopenia: A Post-hoc Analysis of a Prospective Cohort. Cancer Research and Treatment, 2021, 53, 962-972.	3.0	4
149	Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis. Liver Cancer, 2021, 10, 419-432.	7.7	4
150	Postoperative radiotherapy for stage IB carcinoma of the uterine cervix. Yonsei Medical Journal, 1990, 31, 367.	2.2	3
151	Lowâ€Dose Radiationâ€Induced Adaptive Response in the Murine System. Annals of the New York Academy of Sciences, 2002, 973, 255-257.	3.8	3
152	Clinical safety and efficacy of salvage reirradiation for upper abdominal malignancies. Strahlentherapie Und Onkologie, 2019, 195, 526-533.	2.0	3
153	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3123-3133.	2.5	3
154	The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. Oncotarget, 2016, 7, 62715-62725.	1.8	3
155	Prognostic factors and patterns of loco-regional failure in patients with RO resected gallbladder cancer. Hpb, 2020, 22, 1168-1173.	0.3	2
156	The Efficacy of the Change in Belly Board Aperture Location by the Addition of Bladder Compression Device for Radiotherapy of Rectal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2010, 28, 231.	0.1	2
157	Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma. Investigative Magnetic Resonance Imaging, 2019, 23, 351.	0.4	2
158	Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04). Cancer Biology and Medicine, 2022, 19, 1-14.	3.0	2
159	Response to Is radiotherapy the best option for treating hepatocellular carcinoma with <scp>PVTT</scp> ?. Liver International, 2017, 37, 308-309.	3.9	1
160	Curative liver transplantation after lung resection for advanced hepatocellular carcinoma with lung metastasis and inferior vena cava tumor thrombosis: a case report. Journal of Liver Cancer, 2021, 21, 181-186.	1.1	1
161	Superficial Dosimetry for Helical Tomotherapy. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2009, 27, 103.	0.1	1
162	Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors for locally advanced pancreatic cancer patients Journal of Clinical Oncology, 2017, 35, 326-326.	1.6	1

#	Article	lF	Citations
163	Liver-directed concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombus Journal of Clinical Oncology, 2022, 40, 424-424.	1.6	1
164	The role of postoperative radiotherapy in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 123-125.	1.5	1
165	Skull Base Metastasis from Hepatocellular Carcinoma: Clinical Presentation and Efficacy of Radiotherapy. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 357-366.	3.7	1
166	Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablationÂinÂpatients with hepatocellular carcinoma?― Journal of Hepatology, 2020, 73, 468-469.	3.7	0
167	Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers― Journal of Hepatology, 2020, 73, 973-974.	3.7	0
168	Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists., 2021, , 155-168.		0
169	Liver Hypertrophy Following Radiotherapy. , 2021, , 295-302.		0
170	Lymphopenia Following Radiotherapy for Hepatocellular Carcinoma., 2021,, 317-324.		0
171	Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report. Journal of Liver Cancer, 2021, 21, 163-168.	1.1	0
172	Helical tomotherapy and concurrent gemcitabine-based chemotherapy for locally advanced pancreatic cancer Journal of Clinical Oncology, 2012, 30, 318-318.	1.6	0
173	Pattern of failure after hepatic arterial concurrent chemoradiotherapy for locally advanced hepatocellular carcinoma Journal of Clinical Oncology, 2012, 30, 299-299.	1.6	0
174	Dose-escalated radiotherapy with helical tomotherapy to spine oligometastasis from intrahepatic malignancies Journal of Clinical Oncology, 2012, 30, 325-325.	1.6	0
175	Evaluation of Effect of Neoadjuvant Therapy Using Positron Emission Tomography., 2017,, 45-58.		O
176	Can we expect long-term survival in patients with extrahepatic metastasis of hepatocellular carcinoma?. Journal of Clinical Oncology, 2017, 35, 251-251.	1.6	0
177	Establishment of disease-specific graded prognostic assessment for patients with hepatocellular carcinoma and spinal metastasis Journal of Clinical Oncology, 2017, 35, 433-433.	1.6	O
178	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial Journal of Clinical Oncology, 2017, 35, e15678-e15678.	1.6	0
179	Optimal timing of radiotherapy for incomplete transarterial chemoembolization in BCLC stage B hepatocellular carcinoma Journal of Clinical Oncology, 2020, 38, 521-521.	1.6	0
180	Pattern and clinical significance of lymph node metastasis from hepatocellular carcinoma Journal of Clinical Oncology, 2022, 40, 431-431.	1.6	0

#	Article	IF	CITATIONS
181	Early experience of combining immune checkpoint inhibitor and radiotherapy in heavily pretreated hepatobiliary cancer Journal of Clinical Oncology, 2022, 40, 457-457.	1.6	O
182	Implementing combined approach with radiotherapy in surgical strategy for advanced HCC. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S14-S14.	0.1	0
183	Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis. Hepatology International, 2022, , $1.$	4.2	0